References
- Wang Z-Y, Zhu C. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008; 111: 2505–2515.
- Mistry AR, Pedersen EW, Solomon E, Grimwade D. The molecular pathogenesis of acute promyelocytic leukaemia: implica-tions for the clinical management of the disease. Blood Rev 2003; 17: 71–97.
- Sirulnik A, Melnick A, Zelent A, Licht JD. Molecular pathogenesisof acute promyelocytic leukaemia and APL variants. Best Pract Res Clin Haematol 2003; 16: 387–408.
- Sanz MA, Grimwade D, Tallman MS et al. Management of acutepromyelocytic leukemia: recommendations from an expert panel on behalf of the European LeulcemiaNet. Blood 2009; 113: 1875–1891.
- Lo-Coco F, Breccia M, Diverio D. The importance of molecularmonitoring in acute promyelocytic leukemia. Best Pract Res Clin Haematol 2003; 16: 503–520.
- Douer D. New advances in the treatment of acute promyelocyticleukemia. hit J Hematol 2002; 76: 179–187.
- Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99: 759–767.
- Michaeli J, Lerer I, Rachmilewitz EA, Fibach E. Stimulation of proliferation of human myeloid cells in culture: application for cytogenetic analysis. Blood 1986; 68: 790–793.
- Benn PA, Perle MA. Chromosome staining and banding techniques.In: Rooney DE, Czepulkowski BH. (eds) Human cytogenetics: a practical approach, 2nd edn, volume 1, Oxford, Washington DC: IRL Press, 1992; 91–118.
- Shaffer LG, Slovak ML, Campbell Li (eds). An international system for human cytogenetic nomenclature. Basel: S. Karger, 2009.
- Kim M, Lim J, Kim Y et al. The genetic characterization of acutepromyelocytic leukemia with cryptic t(15;17) including a new recurrent additional cytogenetic abnormality i(17)(q10). Leukemia 2008; 22: 881–883.
- Grimwade D, Biondi A, Mozziconacci MJ et al. Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Francais de Cytogenetique Hématologique, Groupe de Francais d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action 'Molecular Cytogenetic Diagnosis in Haematological Malignancies'. Blood 2000; 96: 1297–1308.
- Hiorns LR, Min T, Swansbury GJ, Zelent A, Dyer MJ, Catovsky D. Interstitial insertion of retinoic acid receptor-alpha gene in acute promyelocytic leukemia with normal chromosomes 15 and 17. Blood 1994; 83: 2946–2951.
- Han JY, Kim KE, Kim KH, Park JI, Kim JS. Identification of PML- RARa rearrangement by RT-PCR and sequencing in an acute promyelocytic leukemia without t(15;17) on G-banding and FISH. Leuk Res 2007; 31: 239–243.
- Wang Y, Fang M, Jing Y, Li J, Jiang F, Wang Y. Derivative (7)t(7;8): the sole karyotype abnormality in acute promyelocytic leukemia with PML/RARa rearrangement identified by RT-PCR and sequence analysis. Leuk Res 2009; 33: e55—e58.
- Park TS, Kim JS, Song J et al. Acute promyelocytic leukemia with insertion of PML exon 7a and partial deletion of exon 3 of RARa: a novel variant transcript related to aggressive course and not detected with real-time polymerase chain reaction analysis. Cancer Genet Cytogenet 2009; 188: 103–107.
- Barragan E, Bolufer P, Martin G et al. Identification of two atypical PML-RAR(alpha) transcripts in two patients with acute promyelocytic leukemia. Leuk Res 2002; 26: 439–442.
- Tchinda J, Volpert S, Liersch R et al. A cryptic insertion (17;15) on both chromosomes 17 with lack of PML-RARa expression in a case of atypical acute promyelocytic leukemia. Leukemia 2004; 18: 183–186.
- Han Y, Xue Y, Zhang J, Pan J, Wu Y, Bai S. Y-chromosome loss as the sole karyotypic anomaly with 3'RARa submicroscopic deletion in a case of M3r subtype of acute promyelocytic leukemia. Leuk Res 2009; 33: 1433–1435.
- Zhang L, Mulvihill ii, Kern WF, McMinn J, Li S. Duplication 15q as the sole anomaly in an acute promyelocytic leukemia patient without t(15;17). Cancer Genet Cytogenet 2002; 138: 17–21.
- Hiorns LR, Swansbury GJ, Mehta J et al. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 1997; 96: 314–321.
- Hernández JM, Martin G, Gutierrez NC et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica 2001; 86: 807–813.
- De Botton S, Chevret S, Sanz M et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol 2000; 111: 801–806.